



Publication of insider information pursuant to Art. 17 MAR

Carl Zeiss Meditec AG achieves increase in profit in first quarter 2020/21

Jena, January 19, 2021

Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of EUR 368.9 million in the first quarter of fiscal year 2020/21 (previous year: EUR 369.7 million). This corresponds to a revenue development of -0.2% vs. the past year (after adjustment for currency effects¹: +2.6%).

Earnings before interest and taxes (EBIT)² amounted to EUR 73.4 million in the first quarter of fiscal year 2020/21 (previous year: EUR 56.8 million). EBIT margin (EBIT / revenue) was 19.9% (previous year 15.4%). EBIT development benefitted in part from lower sales and marketing expenses compared to the previous year's period. In addition, EBIT includes a one-time gain from the sale of a property in the amount of around EUR 2.4 million in the current period.

Earnings per share (EPS)³ amounted to EUR 0.52 (previous year: EUR 0.43).

Full results for the first quarter 2020/21 will be published on February 8, 2021.

During the further course of fiscal year 2020/21, the company expects the recovery in revenue and EBIT to continue compared to the previous year, which had seen a marked impact from the COVID-19 pandemic.

Contact for investors and press

Sebastian Frericks
Head of Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: investors.meditec@zeiss.com

¹ Currency-adjusted revenue growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates.

² Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).

³ Earnings per share (also EPS) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated according to IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).

**Brief profile**

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 3,290 employees worldwide, the Group generated revenue of €1,335.5m in fiscal year 2019/20 (to 30 September).

The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/meditec